Compositions of an orally active 1,2,4oxadiazole for nonsense mutation suppression therapy

Details for Australian Patent Application No. 2012238226 (hide)

Owner PTC Therapeutics, Inc.

Inventors Hirawat, Samit; Miller, Langdon

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2012238226

Parent 2006235115

Filing date 5 October 2012

Wipo publication date 25 October 2012

International Classifications

A61K 31/4245 - Oxadiazoles

A61P 3/10 Drugs for disorders of the metabolism

A61P 7/00 Drugs for disorders of the blood or the extracellular fluid

A61P 9/00 Drugs for disorders of the cardiovascular system

A61P 11/00 Drugs for disorders of the respiratory system

A61P 25/00 Drugs for disorders of the nervous system

A61P 25/28 Drugs for disorders of the nervous system

A61P 35/00 Antineoplastic agents

Event Publications

25 October 2012 Application Open to Public Inspection

  Published as AU-A-2012238226

25 October 2012 Complete Application Filed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012238227-Face protector for fastening to safety goggles

2012238225-Method of use of orally administered probiotic bifidobacteria for human beauty benefits